Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic...(ndicated for reducing signs andsymptoms ...),Health

Date:2/22/2008

ndicated for reducing signs and symptoms in patients with active ankylosing spondylitis. HUMIRA is indicated for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-.), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases.

To date, HUMIRA has been approved in 72 countries and more than 250,000 patients worldwide are currently being treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development of innovative treatments for immunologic diseases.

More information about HUMIRA, including full prescribing information and Medication Guide, is available on the Web site http://www.humira.com or in the United States by calling Abbott Medical Information at 1-800-633-9110.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company e
'/>"/>

SOURCE Abbott Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. Abbott Announces 10.8 Percent Increase in Quarterly Dividend
2. On Valentines Day, Abbott Urges Women to Take Heart With Launch of Faces of Heart Disease Exhibit to Raise Heart Health Awareness
3. Abbott Goes Red to Educate Bay Area Women About Heart Disease
4. Abbott to Present at Merrill Lynch Healthcare Conference
5. Abbotts Kaletra(R) and Aluvia(R) (lopinavir/ritonavir) New Lower-Strength Tablet for Pediatric Use Receives Positive Opinion from EMEA
6. Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2007 Earnings
7. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
8. Ugandan Children Are Among the First to Receive Abbotts Lower-Strength Aluvia (lopinavir/ritonavir) Tablet
9. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
10. FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System
11. Abbotts Environmental Protection Initiatives Again Recognized by the State of Illinois